Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Rare Diseases

Syndrome

Preleukemia

Myelodysplastic Syndromes

Bone Marrow Diseases

Hematologic Diseases

Precancerous Conditions

Anti-Infective Agents

All Drugs and Chemicals

Antineoplastic Agents

Anti-Dyskinesia Agents

Anti-Bacterial Agents

Itraconazole

Levofloxacin

Ofloxacin

Cephalosporins

beta-Lactams

Antibiotics, Antitubercular

Mitogens

Clotrimazole

Miconazole

Fluconazole

Trimethoprim, Sulfamethoxazole Drug Combination

Hydroxyitraconazole

Antifungal Agents

Posaconazole

Trimethoprim

Sulfamethoxazole

Enzyme Inhibitors

Cytochrome P-450 Enzyme Inhibitors

Hormones

Hormone Antagonists

Cytochrome P-450 CYP3A Inhibitors

Antiprotozoal Agents

Antiparasitic Agents

Anti-Infective Agents, Local

Antimalarials

Patients affected by myelodysplastic syndrome enrolled in the observational study

Antibiotic and antifungal drugs

Livio Pagano, Dr.

The purpose of this study is to observe the number of new cases of infections per population in a given time period and their characteristics in a pathology (myelodysplastic syndrome, MDS)that involves ineffective production (or dysplasia) of a class of blood cells.

The scarcity and the inadequacy of data make impossible the writing of evidence-based recommendations for prevention and management of infections in myelodysplastic syndrome.

The aim of this study is to evaluate the incidence and the spectrum of the infections of MDS patients. Will be also evaluated potential risk factors.

This study could help the definition of the optimal management of MDS patients in terms of prophylaxis of the infective complications and in terms of the correct administration of growth factors.

Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients

Observational Prospective Multicenter Study to Evaluate the Infective Risk in Myelodysplastic Syndrome Patients: Antimicrobial Prophylaxis and Granulocyte Growth Factors.

Infectious events are fungal and antibiotic events

Gruppo Italiano Malattie EMatologiche dell'Adulto

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients	NCT01951430	Myelodysplastic...	Antibiotic and ...	18 Years -	Gruppo Italiano Malattie EMatologiche dell'Adulto
Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients	NCT01951430	Myelodysplastic...	Antibiotic and ...	18 Years -	Gruppo Italiano Malattie EMatologiche dell'Adulto

Spots Global Cancer Trial Database for antibiotic and antifungal drugs